The California Institute for Regenerative Medicine (CIRM) has awarded $4.7 million to Blue Gen Therapeutics Foundation to advance preclinical development of a novel gene therapy for blue cone monochromacy (BCM), a rare inherited eye disease that severely impairs color vision and visual function. The funding will support research led by Principal Investigator Dr. Aaron Nagiel toward an FDA Investigational New Drug application.
Novel AAV-Based Therapeutic Approach
The project will develop a one-time, intravitreal AAV-based gene therapy designed to deliver a functional copy of the L-opsin gene directly to cone photoreceptor cells in the retina. The treatment aims to restore the function of red and green photoreceptors, which are disrupted by genetic mutations in individuals with BCM.
"This funding decision by CIRM represents a huge milestone for BCM patients, their families, and the entire retinal dystrophy community as we move this therapy further towards clinical trials," Dr. Nagiel said.
Addressing Significant Unmet Medical Need
Blue cone monochromacy is typically diagnosed in infancy and significantly impacts quality of life, causing low vision, light sensitivity, impaired color discrimination, and involuntary eye movements. Current treatments are limited to symptom management, highlighting the urgent need for more effective therapeutic interventions.
The award falls under CIRM's late-stage preclinical projects program, which provides funding for late-stage preclinical studies necessary to attain an active IND with the FDA for stem cell-based or genetic therapy candidates.
Scientific and Clinical Significance
"This award reflects CIRM's commitment to supporting cutting-edge science that has the potential to change lives," said Dr. Shyam Patel, CIRM's Associate Vice President of Preclinical Development. "Blue cone monochromacy is a rare but deeply impactful disease with no meaningful treatment options. We're proud to support Dr. Nagiel and the team at Blue Gen Therapeutics Foundation as they work to advance a potential one-time gene therapy treatment that aims to restore vision and improve quality of life for individuals living with this condition."
The funding represents a critical step toward bringing the first targeted therapy for BCM to clinical development, potentially offering hope to patients and families affected by this rare retinal dystrophy.
